Andrew Goodall
Plus aucun poste en cours
Fortune : 1 M $ au 30/04/2024
Profil
Andrew Ernest Goodall served as a Non-Executive Director at Memphasys Ltd.
from 2012 to 2023.
He also held the same position at PrIME Biologics Pte Ltd.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MEMPHASYS LTD
13,17% | 29/11/2023 | 180 149 529 ( 13,17% ) | 1 M $ | 30/04/2024 |
Anciens postes connus de Andrew Goodall
| Sociétés | Poste | Fin |
|---|---|---|
| MEMPHASYS | Directeur/Membre du Conseil | 30/11/2023 |
PrIME Biologics Pte Ltd.
 PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MEMPHASYS | Health Technology |
| Entreprise privées | 1 |
|---|---|
PrIME Biologics Pte Ltd.
PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Health Technology |